1. S732 Ozanimod Is an Effective Oral Treatment for Patients With Ulcerative Colitis Regardless of Moderate orSevere Endoscopic Disease Activity at Baseline: A Post Hoc Analysis of the Phase 3 True North Study. (October 2022) Authors: Panaccione, Remo; Blumenstein, Irina; Long, Millie; Abraham, Bincy; Jain, Anjali; Memaj, Arteid; Wu, Chun; Hobbs, Vanessa; Harris, Sarah; Canavan, James B.; Peyrin-Biroulet, Laurent Other Names: Wolf Douglas C. presenter. Journal: American journal of gastroenterology Issue: Volume 117:Number 10(2022)supplement 10ES Page Start: e514 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. S811 Evaluation of Ozanimod Efficacy and Safety in Older Patients With Ulcerative Colitis: Post Hoc Analysis From the Phase 3 True North Study. (October 2022) Authors: Irving, Peter; Blumenstein, Irina; Horst, Sara N.; Ahmad, Harris A.; Lawlor, Garrett; Hobbs, Vanessa; Jain, Anjali; Memaj, Arteid; Ananthakrishnan, Ashwin N. Other Names: Khan Nabeel presenter. Journal: American journal of gastroenterology Issue: Volume 117:Number 10(2022)supplement 10ES Page Start: e580 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. S98 Ozanimod Efficacy and Safety in Older Patients With Ulcerative Colitis: A Post Hoc Analysis From True North. (December 2022) Authors: Khan, Nabeel; Irving, Peter; Blumenstein, Irina; Horst, Sara; Ahmad, Harris; Lawlor, Garrett; Hobbs, Vanessa; Jain, Anjali; Memaj, Arteid; Ananthakrishnan, Ashwin Journal: American journal of gastroenterology Issue: Volume 117(2022)Supplement 2022 Page Start: S25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗